Sanofi’s oncology strategy suffers another blow as ADC scrapped over phase 3 lung cancer fail

Sanofi’s cancer strategy has suffered a major blow as the French Big Pharma jettisoned its only clinical-stage antibody-drug conjugate (ADC) after it failed to beat chemotherapy in a phase 3 trial of lung cancer patients.